{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:02Z","timestamp":1794072962880,"version":"4.8.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:p>Hemophilia A, a deficiency of functional coagulation factor VIII (FVIII), is treated via protein replacement therapy. Restoring 1% to 5% of normal blood FVIII activity prevents spontaneous bleeding, making the disease an attractive gene therapy target. Previously, we have demonstrated short-term activity of a liver-specific AAV2 vector expressing canine B-domain-deleted FVIII (cFVIII) in a hemophilia canine model. Here, we report the long-term efficacy and safety of AAV-cFVIII vectors of serotypes 2, 5, 6, and 8 in both hemophilia A mice and dogs. AAV6-cFVIII and AAV8-cFVIII restored physiologic levels of plasma FVIII activity in hemophilia A mice. The improved efficacy is attributed to more efficient gene transfer in liver compared with AAV2 and AAV5. However, supraphysiologic cFVIII levels correlated with the formation of cFVIII-neutralizing antibodies in these mice. Of importance, hemophilia A dogs that received AAV2-cFVIII, AAV6-cFVIII, and AAV8-cFVIII have persistently expressed therapeutic levels of FVIII, without antibody formation or other toxicities, for more than 3 years. However, liver transduction efficiencies are similar between AAV2, AAV6, and AAV8 serotypes in hemophilia A dogs, in contrast to mice. In summary, this is the first report demonstrating multiyear therapeutic efficacy and safety of multiple AAV-cFVIII vectors in hemophilia A dogs and provides the basis for human clinical studies. (Blood. 2006;108:107-115)<\/jats:p>","DOI":"10.1182\/blood-2005-12-5115","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T02:43:37Z","timestamp":1141785817000},"page":"107-115","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":172,"title":["Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs"],"prefix":"10.1182","volume":"108","author":[{"given":"Haiyan","family":"Jiang","sequence":"first","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Patarroyo-White","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyao","family":"Liu","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Qian","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran D.","family":"Scallan","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Powell","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Keller","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"McMurray","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Labelle","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea","family":"Nagy","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Vargas","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhen","family":"Zhou","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B.","family":"Couto","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[{"name":"From Avigen, Alameda, CA; and the Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111823183328400_REF1","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Tuddenham EG. The hemophilias: from royal genes to gene therapy. N Engl J Med. 2001;344: 1773-1779.","DOI":"10.1056\/NEJM200106073442307"},{"key":"2019111823183328400_REF2","doi-asserted-by":"crossref","unstructured":"Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood. 2003;102: 2031-2037.","DOI":"10.1182\/blood-2003-01-0292"},{"key":"2019111823183328400_REF3","doi-asserted-by":"crossref","unstructured":"Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5: 285-297.","DOI":"10.2174\/1566523054065057"},{"key":"2019111823183328400_REF4","doi-asserted-by":"crossref","unstructured":"Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med. 2005;7: 442-451.","DOI":"10.1002\/jgm.686"},{"key":"2019111823183328400_REF5","doi-asserted-by":"crossref","unstructured":"Loiler SA, Conlon TJ, Song S, et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther. 2003;10: 1551-1558.","DOI":"10.1038\/sj.gt.3302046"},{"key":"2019111823183328400_REF6","doi-asserted-by":"crossref","unstructured":"Du L, Kido M, Lee DV, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther. 2004;10: 604-608.","DOI":"10.1016\/j.ymthe.2004.06.110"},{"key":"2019111823183328400_REF7","doi-asserted-by":"crossref","unstructured":"Chen S, Kapturczak M, Loiler SA, et al. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther. 2005;16: 235-247.","DOI":"10.1089\/hum.2005.16.235"},{"key":"2019111823183328400_REF8","doi-asserted-by":"crossref","unstructured":"Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004;10: 302-317.","DOI":"10.1016\/j.ymthe.2004.05.024"},{"key":"2019111823183328400_REF9","doi-asserted-by":"crossref","unstructured":"Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol. 2003;77: 7034-7040.","DOI":"10.1128\/JVI.77.12.7034-7040.2003"},{"key":"2019111823183328400_REF10","doi-asserted-by":"crossref","unstructured":"Ghosh A, Allamarvdasht M, Pan CJ, et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther. 2006;13: 321-329.","DOI":"10.1038\/sj.gt.3302650"},{"key":"2019111823183328400_REF11","doi-asserted-by":"crossref","unstructured":"Liu Y, Okada T, Sheykholeslami K, et al. Specific and efficient transduction of Cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. Mol Ther. 2005;12: 725-733.","DOI":"10.1016\/j.ymthe.2005.03.021"},{"key":"2019111823183328400_REF12","doi-asserted-by":"crossref","unstructured":"Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci. 2005;25: 9321-9327.","DOI":"10.1523\/JNEUROSCI.2936-05.2005"},{"key":"2019111823183328400_REF13","doi-asserted-by":"crossref","unstructured":"Cressant A, Desmaris N, Verot L, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci. 2004;24: 10229-10239.","DOI":"10.1523\/JNEUROSCI.3558-04.2004"},{"key":"2019111823183328400_REF14","doi-asserted-by":"crossref","unstructured":"Auricchio A, O'Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest. 2002;110: 499-504.","DOI":"10.1172\/JCI0215780"},{"key":"2019111823183328400_","doi-asserted-by":"crossref","unstructured":"De B, Heguy A, Leopold PL, et al. Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin. Mol Ther. 2004;10: 1003-1010.","DOI":"10.1016\/j.ymthe.2004.08.022"},{"key":"2019111823183328400_REF16","doi-asserted-by":"crossref","unstructured":"Sandalon Z, Bruckheimer EM, Lustig KH, Rogers LC, Peluso RW, Burstein H. Secretion of a TN-FR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004;78: 12355-12365.","DOI":"10.1128\/JVI.78.22.12355-12365.2004"},{"key":"2019111823183328400_REF17","doi-asserted-by":"crossref","unstructured":"Lotery AJ, Yang GS, Mullins RF, et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther. 2003;14: 1663-1671.","DOI":"10.1089\/104303403322542301"},{"key":"2019111823183328400_REF18","doi-asserted-by":"crossref","unstructured":"Reich SJ, Auricchio A, Hildinger M, et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther. 2003;14: 37-44.","DOI":"10.1089\/10430340360464697"},{"key":"2019111823183328400_REF19","doi-asserted-by":"crossref","unstructured":"Apparailly F, Khoury M, Vervoordeldonk MJ, et al. Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther. 2005;16: 426-434.","DOI":"10.1089\/hum.2005.16.426"},{"key":"2019111823183328400_REF20","doi-asserted-by":"crossref","unstructured":"Mingozzi F, Schuttrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol. 2002;76: 10497-10502.","DOI":"10.1128\/JVI.76.20.10497-10502.2002"},{"key":"2019111823183328400_REF21","doi-asserted-by":"crossref","unstructured":"Blankinship MJ, Gregorevic P, Allen JM, et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther. 2004;10: 671-678.","DOI":"10.1016\/j.ymthe.2004.07.016"},{"key":"2019111823183328400_REF22","doi-asserted-by":"crossref","unstructured":"Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther. 2005;11: 889-898.","DOI":"10.1016\/j.ymthe.2005.01.012"},{"key":"2019111823183328400_REF23","doi-asserted-by":"crossref","unstructured":"Kawamoto S, Shi Q, Nitta Y, Miyazaki J, Allen MD. Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin hybrid promoter. Mol Ther. 2005;11: 980-985.","DOI":"10.1016\/j.ymthe.2005.02.009"},{"key":"2019111823183328400_REF24","doi-asserted-by":"crossref","unstructured":"Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol. 2001;75: 6615-6624.","DOI":"10.1128\/JVI.75.14.6615-6624.2001"},{"key":"2019111823183328400_REF25","doi-asserted-by":"crossref","unstructured":"Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23: 321-328.","DOI":"10.1038\/nbt1073"},{"key":"2019111823183328400_REF26","doi-asserted-by":"crossref","unstructured":"Wang AY, Peng PD, Ehrhardt A, Storm TA, Kay MA. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther. 2004;15: 405-413.","DOI":"10.1089\/104303404322959551"},{"key":"2019111823183328400_REF27","doi-asserted-by":"crossref","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99: 11854-11859.","DOI":"10.1073\/pnas.182412299"},{"key":"2019111823183328400_REF28","doi-asserted-by":"crossref","unstructured":"Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood. 2004;103: 1253-1260.","DOI":"10.1182\/blood-2003-08-2954"},{"key":"2019111823183328400_","doi-asserted-by":"crossref","unstructured":"Wang L, Calcedo R, Nichols TC, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2\/8 mediated, liver-directed gene therapy. Blood. 2005;105: 3079-3086.","DOI":"10.1182\/blood-2004-10-3867"},{"key":"2019111823183328400_REF30","doi-asserted-by":"crossref","unstructured":"Conlon TJ, Cossette T, Erger K, et al. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Mol Ther. 2005;12: 867-875.","DOI":"10.1016\/j.ymthe.2005.05.016"},{"key":"2019111823183328400_REF31","doi-asserted-by":"crossref","unstructured":"Sun B, Zhang H, Franco LM, et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther. 2005;11: 57-65.","DOI":"10.1016\/j.ymthe.2004.10.004"},{"key":"2019111823183328400_REF32","doi-asserted-by":"crossref","unstructured":"Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5: 56-63.","DOI":"10.1038\/4743"},{"key":"2019111823183328400_REF33","doi-asserted-by":"crossref","unstructured":"Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost. 2004;30: 205-213.","DOI":"10.1055\/s-2004-825634"},{"key":"2019111823183328400_REF34","doi-asserted-by":"crossref","unstructured":"Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol. 1998;72: 309-319.","DOI":"10.1128\/JVI.72.1.309-319.1998"},{"key":"2019111823183328400_REF35","doi-asserted-by":"crossref","unstructured":"Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998;5: 938-945.","DOI":"10.1038\/sj.gt.3300680"},{"key":"2019111823183328400_REF36","doi-asserted-by":"crossref","unstructured":"Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 2003;102: 2412-2419.","DOI":"10.1182\/blood-2003-02-0495"},{"key":"2019111823183328400_REF37","doi-asserted-by":"crossref","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10: 119-121.","DOI":"10.1038\/ng0595-119"},{"key":"2019111823183328400_REF38","unstructured":"National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1985. NIH publication no. 85-23."},{"key":"2019111823183328400_REF39","doi-asserted-by":"crossref","unstructured":"Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34: 612.","DOI":"10.1055\/s-0039-1689482"},{"key":"2019111823183328400_REF40","doi-asserted-by":"crossref","unstructured":"Sommer JM, Smith PH, Parthasarathy S, et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther. 2003;7: 122-128.","DOI":"10.1016\/S1525-0016(02)00019-9"},{"key":"2019111823183328400_REF41","unstructured":"Feingold HM, Pivacek LE, Melaragno AJ, Valeri CR. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am J Vet Res. 1986;47: 2197-2199."},{"key":"2019111823183328400_REF42","doi-asserted-by":"crossref","unstructured":"Hough C, Kamisue S, Cameron C, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost. 2002;87: 659-665.","DOI":"10.1055\/s-0037-1613063"},{"key":"2019111823183328400_REF43","doi-asserted-by":"crossref","unstructured":"Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood. 1982;60: 727-730.","DOI":"10.1182\/blood.V60.3.727.727"},{"key":"2019111823183328400_REF44","doi-asserted-by":"crossref","unstructured":"Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73: 3994-4003.","DOI":"10.1128\/JVI.73.5.3994-4003.1999"},{"key":"2019111823183328400_REF45","doi-asserted-by":"crossref","unstructured":"Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002;76: 791-801.","DOI":"10.1128\/JVI.76.2.791-801.2002"},{"key":"2019111823183328400_REF46","unstructured":"Qu G, Bahr-Davidson J, Prado J, et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors using anion-exchange column chromatography. Mol Ther. In press."},{"key":"2019111823183328400_REF47","doi-asserted-by":"crossref","unstructured":"Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6: 973-985.","DOI":"10.1038\/sj.gt.3300938"},{"key":"2019111823183328400_REF48","doi-asserted-by":"crossref","unstructured":"Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005;11: 875-888.","DOI":"10.1016\/j.ymthe.2004.12.022"},{"key":"2019111823183328400_REF49","doi-asserted-by":"crossref","unstructured":"Ye P, Thompson AR, Sarkar R, et al. Naked DNA transfer of factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther. 2004;10: 117-126.","DOI":"10.1016\/j.ymthe.2004.04.009"},{"key":"2019111823183328400_REF50","doi-asserted-by":"crossref","unstructured":"Balague C, Zhou J, Dai Y, et al. Sustained highlevel expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood. 2000;95: 820-828.","DOI":"10.1182\/blood.V95.3.820.003k32_820_828"},{"key":"2019111823183328400_REF51","doi-asserted-by":"crossref","unstructured":"Gallo-Penn AM, Shirley PS, Andrews JL, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood. 2001;97: 107-113.","DOI":"10.1182\/blood.V97.1.107"},{"key":"2019111823183328400_REF52","doi-asserted-by":"crossref","unstructured":"Qian J, Borovok M, Bi L, Kazazian HH Jr, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost. 1999;81: 240-244.","DOI":"10.1055\/s-0037-1614450"},{"key":"2019111823183328400_REF53","doi-asserted-by":"crossref","unstructured":"Chao H, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood. 2001;97: 3311-3312.","DOI":"10.1182\/blood.V97.10.3311"},{"key":"2019111823183328400_REF54","doi-asserted-by":"crossref","unstructured":"High KA. Clinical gene transfer studies for hemophilia B. Semin Thromb Hemost. 2004;30: 257-267.","DOI":"10.1055\/s-2004-825639"},{"key":"2019111823183328400_","doi-asserted-by":"crossref","unstructured":"Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24: 257-261.","DOI":"10.1038\/73464"},{"key":"2019111823183328400_","doi-asserted-by":"crossref","unstructured":"Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101: 2963-2972.","DOI":"10.1182\/blood-2002-10-3296"},{"key":"2019111823183328400_","doi-asserted-by":"crossref","unstructured":"Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99: 2670-2676.","DOI":"10.1182\/blood.V99.8.2670"},{"key":"2019111823183328400_","doi-asserted-by":"crossref","unstructured":"Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5: 64-70.","DOI":"10.1038\/4751"},{"key":"2019111823183328400_REF59","doi-asserted-by":"crossref","unstructured":"Manno CS, Pierce GF, Glader B, et al. AAV-mediated, liver-directed gene transfer for severe hemophilia B: successful transduction and limitations imposed by the host immune response. Nat Med. 2006;12: 342-347.","DOI":"10.1038\/nm1358"},{"key":"2019111823183328400_REF60","doi-asserted-by":"crossref","unstructured":"Landskroner KA, Olson NC, Jesmok GJ. Enhanced factor VIII activity measurements using ROTEG and factor VIII-\/-mice whole blood. J Thromb Haemost. 2004;2: 2274-2275.","DOI":"10.1111\/j.1538-7836.2004.01074.x"},{"key":"2019111823183328400_REF61","doi-asserted-by":"crossref","unstructured":"Landskroner KA, Olson NC, Jesmok GJ. Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII. Haemophilia. 2005;11: 346-352.","DOI":"10.1111\/j.1365-2516.2005.01104.x"},{"key":"2019111823183328400_REF62","doi-asserted-by":"crossref","unstructured":"Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 2004;103: 85-92.","DOI":"10.1182\/blood-2003-05-1446"},{"key":"2019111823183328400_REF63","doi-asserted-by":"crossref","unstructured":"Zhang N, Clement N, Chen D, et al. Transduction of pancreatic islets with pseudotyped adeno-associated virus: effect of viral capsid and genome conversion. Transplantation. 2005;80: 683-690.","DOI":"10.1097\/01.tp.0000173381.97556.0d"},{"key":"2019111823183328400_REF64","doi-asserted-by":"crossref","unstructured":"Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low neutralizing titers in SCID mice. Blood. 2006;107: 1810-1817.","DOI":"10.1182\/blood-2005-08-3229"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/1\/107\/470913\/zh801306000107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/1\/107\/470913\/zh801306000107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T02:41:25Z","timestamp":1586745685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/1\/107\/133562\/Multiyear-therapeutic-benefit-of-AAV-serotypes-2-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-12-5115","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]}}}